Anti-Mouse IFN gamma SAFIRE Purified

Grouped product items
Size Price Qty
50ug
$110.00
500ug
$320.00

Additional R4-6A2 Formats

Cat.No. Format Starting From
80822-25 SAFIRE Purified $ 110.00
Catalog Number : 80822-25

description

The R4-6A2 monoclonal antibody specifically reacts with mouse interferon gamma (IFN-g), an acid-labile interferon produced by CD4 and CD8 T lymphocytes as well as activated NK cells. IFN gamma receptors are present in most immune cells, which respond to its signaling by increasing the surface expression of class I MHC proteins. This promotes the presentation of antigen to T-helper (CD4+) cells. Additionally, it stimulates a number of lymphoid cell functions, including the anti-microbial and anti-tumor responses of macrophages, NK cells, and neutrophils.

Additional Information

Clone:
R4-6A2
Format:
SAFIRE Purified
Applications:
FA
Reactivity:
Mouse
Isotype:
Rat IgG1, kappa
Research Interest: Innate Immunity, Adaptive Immunity
Cell Type: NK and NKT Cells, T Cells
Application: FA
Clone: R4-6A2
Preparation:
The product should be stored undiluted at 4°C. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography.
Formulation:
Phosphate-buffered aqueous solution, ph7.2.
References:

Spitalny, G. L., & Havell, E. A. (1984). Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. The Journal of experimental medicine159(5), 1560-1565.

Grau, G. E., Heremans, H., Piguet, P. F., Pointaire, P., Lambert, P. H., Billiau, A., & Vassalli, P. (1989). Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proceedings of the National Academy of Sciences86(14), 5572-5574.

Sadick, M. D., Heinzel, F. P., Holaday, B. J., Pu, R. T., Dawkins, R. S., & Locksley, R. M. (1990). Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. The Journal of experimental medicine171(1), 115-127.

© BioGems International, Inc. All rights reserved.